Radiant Bio Closes $35 Million Series A Financing

Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver transformative therapies for patients facing life-changing disease, recently announced it has closed a $35 million Series A financing. Radiant has built a best-in-class, proprietary, multi-valent, multi-specific antibody platform called Multabody™. The funds will enable Radiant to further develop the company’s lead clinical candidate, 4-1BB, and move it towards clinical trials.